|
|
|
|
|
|
|
|
abstract
Background.
Dexamethasone-induced hiccup (DIH) is an underrecognized symptom in
patients with cancer, and little information is available
about its treatment. The aims of this study were
to investigate the feasibility of methylprednisolone rotation as
treatment
and to confirm the male predominance among those
with cancer who experienced DIH during chemotherapy.
Methods. Persons with
cancer who experienced hiccups during chemotherapy treatment and who
were receiving treatment with dexamethasone
were presumed to have DIH. The following
algorithmic practice was implemented for antiemetic corticosteroid use:
rotation
from dexamethasone to methylprednisolone in the
next cycle and dexamethasone re-administration in the second cycle of
chemotherapy
after recognition of hiccups to confirm DIH. All
other antiemetics except corticosteroid remained unchanged. Patients (n = 40) were recruited from eight cancer centers in Korea from September 2012 to April 2013. Data were collected retrospectively.
Results. Hiccup
intensity (numeric rating scale [NRS]: 5.38 vs. 0.53) and duration
(68.44 minutes vs. 1.79 minutes) were significantly
decreased after rotation to methylprednisolone,
while intensity of emesis was not increased (NRS: 2.63 vs. 2.08). Median
dose
of dexamethasone and methylprednisolone were 10
mg and 50 mg, respectively. Thirty-four (85%) of 40 patients showed
complete
resolution of hiccups after methylprednisolone
rotation in the next cycle. Of these 34 patients, 25 (73.5%) had
recurrence
of hiccups after dexamethasone
re-administration. Compared with baseline values, hiccup intensity (NRS:
5.24 vs. 2.44) and
duration (66.43 minutes vs. 22.00 minutes) were
significantly attenuated after dexamethasone re-administration. Of the
40
eligible patients, 38 (95%) were male.
Conclusion. DIH during
chemotherapy could be controlled without losing antiemetic potential by
replacing dexamethasone with methylprednisolone.
We also identified a male predominance of DIH.
Further prospective studies are warranted.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.